Skip to main content

Table 1 Patient demographics and characteristics

From: Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative

Parameter

All patients diagnosed with stage IIIB–IV NSCLC

(2012–2016)

Patients diagnosed

with stage IIIB–IV NSCLC

in 2012–2014

(no treatment data available)

Patients diagnosed with stage IIIB–IV NSCLC in 2015–2016 (treatment data available)

P valuea

All

N = 1008

All

N = 616

All

N = 392

 

Median age (IQR), years

65 (58–73)

66 (58–74)

65 (57–72)

 

Age range

21–92

21–92

27–90

 

Age at diagnosis in years, n (%)

   

0.854

  < 65

478 (47.4)

288 (46.8)

190 (48.5)

 65–74

307 (30.5)

189 (30.7)

118 (30.1)

  ≥ 75

223 (22.1)

139 (22.6)

84 (21.4)

Sex, n (%)

   

0.316

 Male

762 (75.6)

459 (74.5)

303 (77.3)

 Female

246 (24.4)

157 (25.5)

89 (22.7)

TNM stage, n (%)

   

0.290

 IIIB

154 (15.3)

100 (16.2)

54 (13.8)

 IV

854 (84.7)

516 (83.8)

338 (86.2)

Histology, n (%)

   

0.043

 NSQ

720 (71.4)

431 (70.0)

289 (73.7)

 Adenocarcinoma

713 (70.7)

429 (69.6)

284 (72.4)

 SQ

210 (20.8)

127 (20.6)

83 (21.2)

 NSCLC NOS

57 (5.7)

45 (7.3)

12 (3.1)

 Other histologies

21 (2.1)

13 (2.1)

8 (2.0)

  1. NA not available, NSCLC non-small cell lung cancer, SD standard deviation, IQR interquartile range, TNM tumour, node, and metastasis, NSQ non-squamous cell carcinoma, SQ squamous cell carcinoma, NOS not otherwise specified
  2. a Chi-square test